Wednesday, March 3, 2010

Novel compound found effective against avian influenza virus (H5N1)....

Currently, two neuraminidase (NA) inhibitors, oseltamivir and zanamivir, which must be administrated twice daily for 5 days for maximum therapeutic effect, are licensed for the treatment of influenza. However, oseltamivir-resistant mutants of seasonal H1N1 and highly pathogenic H5N1 avian influenza A viruses have emerged. Therefore, alternative antiviral agents are needed.

Now  researchers from Japan,  lead by Yoshihiro Kawaoka,  have come up with a new neuraminidase inhibitor, R-125489, and its prodrug, CS-8958.  CS-8958 functions as a long-acting NA inhibitor in vivo (mice) and is efficacious against seasonal influenza strains following a single intranasal dose.

As per the claim by the researchers, R-125489 interferes with the NA activity of H5N1 viruses, including oseltamivir-resistant and different clade strains. A single dose of CS-8958 (1,500 µg/kg) given to mice 2 h post-infection with H5N1 influenza viruses produced a higher survival rate than did continuous five-day administration of oseltamivir (50 mg/kg twice daily).

Researchers conclude that, CS-8958 is a promising candidate for a new neuraminidase inhibitor to prevent and treat influenza patients infected with H5N1 and other subtype viruses... 

Ref : Yoshihiro Kawaoka et. al., PLoS Pathogens Feb., 2010

No comments: